Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis
June 24, 2019LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference call on Tuesday, June 25, 2019 at 8:00 a.m. Eastern Time to provide top-line results from the SOLACE trial of topical ocular reproxalap in patients with noninfectious anterior uveitis.
The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID is 8856138. A live, listen-only audio webcast of the conference call can be accessed on the investor relations page of Aldeyra’s corporate website at ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for thirty days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra’s product candidates have been approved for sale in the U.S. or elsewhere.
Contacts
Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
[email protected]
Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
Tel: 339-970-2843
[email protected]
Media Contact:
Sean Leous
Westwicke, an ICR Company
Tel: 646-677-1839
[email protected]